PT - JOURNAL ARTICLE AU - Martinez-Carrasco, Alejandro AU - Real, Raquel AU - Lawton, Michael AU - Iwaki, Hirotaka AU - Tan, Manuela M. X. AU - Wu, Lesley AU - Williams, Nigel M. AU - Carroll, Camille AU - Hu, Michele T.M. AU - Grosset, Donald G. AU - Hardy, John AU - Ryten, Mina AU - Foltynie, Tom AU - Ben-Shlomo, Yoav AU - Shoai, Maryam AU - Morris, Huw R. TI - Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease AID - 10.1101/2023.05.24.23290362 DP - 2023 Jan 01 TA - medRxiv PG - 2023.05.24.23290362 4099 - http://medrxiv.org/content/early/2023/05/30/2023.05.24.23290362.short 4100 - http://medrxiv.org/content/early/2023/05/30/2023.05.24.23290362.full AB - Importance Forty percent of Parkinson’s disease patients develop levodopa-induced-dyskinesia (LiD) within 4 years of starting levodopa. The genetic basis of LiD remains poorly understood, and there have been few well powered studies.Objective To discover common genetic variants in the PD population that increase the probability of developing LiD.Design, setting and Participants We performed survival analyses to study the development of LiD in 5 separate longitudinal cohorts. We performed a meta-analysis to combine the results of genetic association from each study based on a fixed effects model weighting the effect sizes by the inverse of their standard error. The selection criteria was specific to each cohort. We studied individuals that were genotyped from each cohort and that passed our analysis specific inclusion criteria.Main Outcomes and Measures We measured the time for PD patients on levodopa treatment to develop LiD as defined by reaching a score higher or equal than 2 from the MDS-UPDRS part IV, item 1, which is equivalent to a range of 26%-50% of the waking time with dyskinesia. We carried out a genome-wide analysis of the hazard ratio and the association of genome-wide SNPs with the probability of developing LiD using cox proportional hazard models (CPH).Results This study included 2,784 PD patients of European ancestry, of whom 14.6% developed LiD. Consistent with previous studies, we found female gender (HR = 1.35, SE = 0.11, P = 0.007) and younger age at onset (HR = 1.8, SE = 0.14, P = 2 × 10−5) to increase the probability of developing LiD. We identified three loci significantly associated with time-to-LiD onset. rs72673189 on chromosome 1 (HR = 2.77, SE = 0.18, P = 1.53 × 10−8) located in the LRP8 locus, rs189093213 on chromosome 4 (HR = 3.06,, SE = 0.19, P = 2.81 × 10−9) in the non-coding RNA LINC02353 locus, and rs180924818 on chromosome 16 (HR = 3.13, SE = 0.20, P = 6.27 × 10−9) in the XYLT1 locus. Subsequent colocalization analyses on chromosome 1 identified DNAJB4 as a candidate gene associated with LiD through a change in gene expression. We computed a PRS based on our GWAS meta-analysis and found high accuracy to stratify between PD-LID and PD (AUC 83.9). We also performed a stepwise regression analysis for baseline features selection associated with LiD status. We found baseline anxiety status to be significantly associated with LiD (OR = 1.14, SE = 0.03, P = 7.4 × 10−5). Finally, we performed a candidate variant analysis and found that genetic variability in ANKK1 (rs1800497, Beta = 0.24, SE = 0.09, P = 8.89 × 10−3) and BDNF (rs6265, Beta = 0.19, SE = 0.10, P = 4.95 × 10−2) loci were significantly associated with time to LiD in our large meta-analysis.Conclusion In this association study, we have found three novel genetic variants associated with LiD, as well as confirming reports that variability in ANKK1 and BDNF loci were significantly associated with LiD probability. A PRS nominated from our time-to-LiD meta-analysis significantly differentiated between PD-LiD and PD. In addition, we have found female gender, young PD onset and anxiety to be significantly associated with LiD.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://github.com/AMCalejandro/LID-CPH.git Funding StatementThis research was funded in whole or in part by Aligning Science Across Parkinson’s [Grant number: ASAP-000478] through the Michael J. Fox Foundation for Parkinson’s Research (MJFF).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:TPD has multi-centre research ethics approval from the West of Scotland Research Ethics Committee (REC reference: 11/AL/0163). OPDC has multi-centre research ethics approval from the South Central Oxford A Research Ethics Committee (REC reference: 16/SC/0108). AMP-PD clinical data collection and DNA samples were obtained with local institutional and ethical approvals (details can be obtained from the https://amp-pd.org and each study website). PD-STAT has been approved by the North East-Newcastle and North Tyneside 2 Research Ethics Committee (ClinicalTrials.gov NCT02787590). All subjects provided written informed consent. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced are available online at https://doi.org/10.5281/zenodo.7795604 https://doi.org/10.5281/zenodo.7795604